Inventor
GEORGE D. YANCOPOULOS
Inventor
US
Overview
Patents· 23 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Kprimary
C07KPeptides25%
A61KPreparations for medical, dental or toiletry purposes24%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations20%
C12NMicroorganisms or enzymes14%
A01KAnimal husbandry8%
Y02ATechnologies for adaptation to climate change4%
A61DVeterinary instruments, implements, tools, or methods1%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms1%
G01NInvestigating or analysing materials by determining their chemical or physical properties1%
PatentTitleYear
12,496,470Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments202512,441,800Bispecific anti-PSMA x anti-CD28 antibodies and uses thereof202512,415,856EGFR x CD28 multispecific antibodies202512,402,611Genetically modified mice and engraftment202512,268,730Use of a VEGF antagonist to treat angiogenic eye disorders202512,251,440Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments202512,162,943High affinity human antibodies to human IL-4 receptor202412,127,536Humanized M-CSF mice202412,037,596Targeted modification of rat genome202411,986,511Use of a VEGF antagonist to treat angiogenic eye disorders202411,964,016Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy202411,912,767EGFR x CD28 multispecific antibodies202411,866,503Methods for treating inflammatory conditions of the airway or lungs by administering antagonist monoclonal antibodies to interleukin-33 and interleukin-4 receptor202411,820,997Methods and compositions for the targeted modification of a genome202311,778,995Genetically modified non-human animals and methods of use thereof202311,732,030Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments202311,697,828Methods and compositions for targeted genetic modification using paired guide RNAs202311,576,356Genetically modified non-human animals and methods of use thereof202311,559,564Use of a VEGF antagonist to treat angiogenic eye disorders202311,548,947Bispecific anti-PSMA X anti-CD28 antibodies and uses thereof202311,453,721Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereof202211,396,544Bispecific anti-CD28 x anti-CD22 antibodies and uses thereof202211,352,417Method of treating an allergy with allergen-specific monoclonal antibodies2022Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2022–2025Patents assigned to REGENERON PHARMA (23)· patent assignee history
2022–2023Patents assigned to REGENERAN PHARMACEUTICALS INC (2)· patent assignee history
2022–2025Based in US· patent location history
2023–2025Patents assigned to INSTITUTE FOR RES IN BIOMEDICINE IRB (4)· patent assignee history
2023–2025Patents assigned to UNIV YALE (4)· patent assignee history
2023Patents assigned to REGENEREN PHARMACEUTICALS INC (1)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| REGENERON PHARMA | 23 | 2022–2025 |
| INSTITUTE FOR RES IN BIOMEDICINE IRB | 4 | 2023–2025 |
| UNIV YALE | 4 | 2023–2025 |
| REGENERAN PHARMACEUTICALS INC | 2 | 2022–2023 |
| REGENEREN PHARMACEUTICALS INC | 1 | 2023 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 23 | 2022–2025 |